US Prostate Cancer Conference (USPCC) | Conference

Dr Sartor on PSMA PET and Radioligand Therapy in Prostate Cancer

March 13th 2024

Oliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.

Dr Sartor on Ongoing Prostate Cancer Research

March 13th 2024

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Dr Calais on Controversies in the Treatment of Patients With Prostate Cancer

March 13th 2024

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

March 12th 2024

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Dr Agarwal on QOL Considerations for Patients With Prostate Cancer

March 11th 2024

Neeraj Agarwal, FASCO, MD, discusses quality of life considerations for patients with prostate cancer.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

March 11th 2024

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

March 11th 2024

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Dr. Koo on Novel Technological and Therapeutic Advancements in Prostate Cancer

March 1st 2023

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

New Options Poised to Make a Splash in Metastatic Prostate Cancer

February 21st 2023

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer

February 21st 2023

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

New Technology Advances Prostate Cancer Care But Questions Linger

February 21st 2023

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Dr. Zhang on the Use of PARP Inhibitor–based Combinations in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care

February 21st 2023

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .